ライフサイエンスコーパス: local recurrence

1 m in thickness and >=0.5 mm in LBD indicated local recurrence.

2 cervical carcinoma and evaluate the risk of local recurrence.

3 patients undergo additional surgery to avoid local recurrence.

4 The primary endpoint was local recurrence.

5 T after BCS on the basis of risk factors for local recurrence.

6 ermic intraperitoneal chemotherapy will have local recurrence.

7 to stratify patients on the basis of risk of local recurrence.

8 ion seems to be an important risk factor for local recurrence.

9 29 months, 6 patients (3%) have experienced local recurrence.

10 term tumor surveillance, perhaps more so for local recurrence.

11 f 982 patients, 35 patients (3.6%) developed local recurrence.

12 May 1998 and December 2008 were reviewed for local recurrence.

13 tic potential but with a significant risk of local recurrence.

14 m to effect a latent phenotype that precedes local recurrence.

15 ain by hypothetical top-down modification of local recurrence.

16 97.6%); 2 patients underwent enucleation for local recurrence.

17 es only if V1 operates in a regime of strong local recurrence.

18 ho did not undergo a second operation showed local recurrence.

19 year DSS was 86% and 1 patient experienced a local recurrence.

20 c leak predisposes rectal cancer patients to local recurrence.

21 se patients are also at significant risk for local recurrence.

22 only 8 of 66 (12.1%) patients had exclusive local recurrence.

23 tatus were all significantly associated with local recurrence.

24 s also associated with an increased risk for local recurrence.

25 uggest young age is a predictor of increased local recurrence.

26 iate considering the anatomy and etiology of local recurrences.

27 For rectal cancer, an increase of local recurrences (13.3% vs 4.6%; hazard ratio 2.96; 95%

28 ed no statistical differences in outcomes of local recurrence (14% vs. 15%), enucleation (14% vs. 11%

29 pancreatic cancer (17 months) and those with local recurrence (16 months).

30 /250); from these, 65.2% (45 patients) had a local recurrence, 18.8% (13 patients) a single lymph nod

31 e (1) what constitutes an acceptable risk of local recurrence, (2) what are the costs associated with

32 Among 61 patients with local recurrence, 32 patients (52.4%) were correctly dia

33 in 27% of patients who experienced isolated local recurrence, 33% of patients with a distant recurre

34 CPNI compared with those with CSCC and IPNI (local recurrence, 37% vs 17%; P < .001; disease-specific

35 erential resection margin, mesorectal grade, local recurrence (4% vs 5%, P = 0.98), and disease-free

36 Local recurrence (5-year, 51% vs. 54%, P = 0.11) and ove

37 nd prosthesis fracture (1 patient, 0.6%) and local recurrence (6 patients, 3.9%).

38 with no response, experienced lower rates of local recurrence (6% v.

39 n CAP45 and CAPOX50 (cumulative incidence of local recurrence, 6.1% v 4.4%; overall survival, 87.6% v

40 detect 116 lesions in 49.6% of patients (22 local recurrences, 63 lymph nodes, and 31 distant metast

41 (4.9 +/- 5.3 vs. 2.2 +/- 3.7, P = 0.02, for local recurrence; 9.8 +/- 9.7 vs. 2.3 +/- 2.6, P < 0.001

42 Seventeen eyes (85%) showed no local recurrence after a median follow-up of 65 months (

43 Clinical awareness of increased risk of local recurrence after anastomotic leakage throughout th

44 ifocal disease that carries <10% risk of any local recurrence after breast-conserving surgery alone.

45 iting policy with intervention when invasive local recurrence after breast-conserving surgery is dete

46 did not expose patients to complications or local recurrence after enucleation.

47 umferential resection margin on survival and local recurrence after esophagectomy are conflicting.

48 Increased local recurrence after excision of the primary tumors wa

49 histology predicts the 3- and 5-year risk of local recurrence after limb-sparing surgery in the absen

50 lvage radiotherapy with patients with PSA or local recurrence after prostatectomy.

51 eyond the margins of the main tumor mass and local recurrence after surgery.

52 Local recurrence after transarterial embolization (TAE)

53 variable analyses, with an endpoint of first local recurrence after treatment in a tertiary centre.

54 treatment at participating centre, and first local recurrence after treatment.

55 The rate of local recurrences after breast-conserving therapy did no

56 Treatment failure included local recurrence alone in 75 patients (14%) and systemic

57 ch might inform shared decision making while local recurrence analysis is pending.

58 /161 [3.1%]) with iris melanoma demonstrated local recurrence and 1 metastasized.

59 section margin is the primary determinant of local recurrence and a major factor in survival in recta

60 including only size, site, and age predicts local recurrence and can aid in counseling patients.

61 resectable MRD, PNB-guided surgery prevented local recurrence and delivered 100% tumour-free survival

62 th CSCC and CPNI are at an increased risk of local recurrence and disease-specific death compared wit

63 The overall risks of local recurrence and disease-specific death were signifi

64 Five-year crude cumulative incidences of local recurrence and distant metastasis for radical vers

65 moresistance is considered the main cause of local recurrence and distant metastasis in lung cancer.

66 roenvironment, significantly preventing both local recurrence and distant metastasis in malignant mel

67 ative breast cancer (TNBC) has high rates of local recurrence and distant metastasis, partially due t

68 drug resistance) are likely to give rise to local recurrence and distant metastatic relapse.

69 sion alone is associated with a high risk of local recurrence and inferior survival compared with tra

70 Suspicion of local recurrence and inflammation required a biopsy conf

71 Local recurrence and inflammation were confirmed by a bi

72 Score in estimating the risk of ipsilateral local recurrence and ipsilateral invasive breast cancer

73 r depth is associated with the highest RR of local recurrence and metastasis of cSCC, and tumor diame

74 have a poor prognosis owing to high rates of local recurrence and metastasis to distant organs.

75 t create a regenerative environment favoring local recurrence and metastasis.

76 r treatment have improved survival; however, local recurrence and metastatic disease-the principal ca

77 After achievement of a cCR, the risk for local recurrence and need for salvage surgery is similar

78 onstitutes the most important determinant of local recurrence and overall survival, and patients with

79 r positive or negative) for the diagnosis of local recurrence and pelvic LN and bone metastases was m

80 Documented local recurrence and pelvic LN and bone metastases was p

81 R imaging versus PET/CT for the diagnosis of local recurrence and pelvic LN and bone metastases were

82 ion margin is associated with a high rate of local recurrence and poor morbidity and mortality for re

83 nd suggest that serum LIF levels may predict local recurrence and radiosensitivity in NPC patients.

84 sess clinical and surgical factors affecting local recurrence and survival in young breast cancer pat

85 We report 5-year results for local recurrence and the first analysis of overall survi

86 ncer is accepted as the best means to reduce local recurrence and thereby improve survival, there is

87 ), four out of 27 patients (14.8%) developed local recurrence and underwent salvage total laryngectom

88 mary site, we found a low occurrence of true local recurrences and satellite recurrences.

89 rgery alone, patients may remain at risk for local recurrences and/or metastatic disease.

90 monstrated metastases, there were 2 cases of local recurrence, and 16% (n = 21) underwent enucleation

91 etastatic spread to the surgical bed causing local recurrence, and another case of cross-metastatic s

92 hat are the benefits of endocrine therapy on local recurrence, and do they justify the additional tox

93 pe and is associated with indolent behavior, local recurrence, and insensitivity to radiotherapy and

94 idity, mortality, complications, radicality, local recurrence, and metastasis.

95 er T stage was significantly associated with local recurrence, and recurrent tumors had a 4-fold incr

96 included perioperative morbidity, mortality, local recurrence, and survival.

97 survival, cancer-specific 5-year mortality, local recurrence, and the development of metastatic dise

98 ction of the primary tumor, and up to 66% of local recurrences are associated with positive margins.

99 me show malignant morphological features and local recurrences are not uncommon; a few may even metas

100 Local recurrences arise from latent tumor cells that sur

101 t lesions in 64 of 107 patients (59.8%), and local recurrence as well as distant lesions in 25 of 107

102 Local recurrence at 3 years was collected from the regis

103 OLOR II trial were disease-free survival and local recurrence at 3-year follow-up, respectively, and

104 Primary endpoint was local recurrence at 3-year follow-up.

105 local control in older women at low risk of local recurrence at 5 years.

106 this study, 14 of 26 (54%) have developed a local recurrence at a median of 20.0 months (20.5, 4.7-6

107 ed by biopsy for all patients in the case of local recurrence before surgery.

108 Margins up to 0.5 mm offers a local recurrence benefit but does not confer survival be

109 dal involvement was significantly related to local recurrence but more strongly related to distant me

110 esection, whole brain radiotherapy decreases local recurrence, but might cause cognitive decline.

111 argins are associated with increased risk of local recurrence, but there is no consensus regarding op

112 s (52.4%) were correctly diagnosed as having local recurrence by both multiparametric MR imaging and

113 RT was associated with significantly reduced local recurrence compared with conventional EBRT for pri

114 SRS) to the surgical cavity improved time to local recurrence compared with that for surgical resecti

115 three brain metastases significantly lowers local recurrence compared with that noted for observatio

116 what are the costs associated with managing local recurrences compared with RT given initially after

117 tive findings was observed for primary tumor/local recurrence (CT, 18%, vs. PET/CT, 37%), pelvic lymp

118 After IRE, local recurrence developed in 23 of the 50 participants

119 Local recurrence developed in 3 patients; 1 of them unde

120 was no association between clinical leak and local recurrence, disease-free survival, or overall surv

121 re correlated to the cumulative incidence of local recurrence, distant metastasis, and disease-free s

122 this information along with outcome data for local recurrence, distant recurrence, disease specific,

123 ion therapy is effective against this tumor, local recurrence due to radioresistance is an important

124 referred to salvage surgery in the event of local recurrence during follow-up.

125 avoiding ADT, reducing rates of symptomatic local recurrence, enabling full pathological tumour stag

126 is the reason for a relatively high rate of local recurrence, even after surgical removal.

127 ntly demonstrated a reduction in the risk of local recurrence following breast-conserving surgery (BC

128 This case highlights a local recurrence following use of this new treatment mod

129 Local recurrences following brachytherapy are uncommon 5

130 ted in a significant but modest reduction in local recurrence for women aged 65 years or older with e

131 tastases; in the SABR group, one patient had local recurrence, four had regional nodal recurrence, an

132 The primary endpoint was local recurrence free survival (RFS) and the secondary e

133 Local recurrence free survival was significantly differe

134 ons between margins and overall survival and local recurrence free survival were explored using Kapla

135 Margins >0.5 mm were not predictive of local recurrence free survival.

136 nts with R0 versus R1 margins (2- and 5-year local recurrence free survivals of 53.5% and 20.4% vs 25

137 which translated to 55% and 76% overall and local recurrence-free 5-year survival in those with colo

138 The 2-year local recurrence-free rate, distant metastasis-free rate

139 Primary outcomes were overall survival (OS), local recurrence-free survival (L-RFS), and metastasis-f

140 ess associations with the primary endpoints: local recurrence-free survival (LRFS) and disease-specif

141 were 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS).

142 s no statistically significant difference in local recurrence-free survival (P = 0.13).

143 nal wall tumors had the best outcome (5-year local recurrence-free survival rate of 91%).

144 Five-year local recurrence-free survival was 69%.

145 Three-year estimated local recurrence-free survival was 89.2% (95% CI, 0.748

146 Efficacy end points were local recurrence-free survival, metastasis-free survival

147 t radiation was not associated with improved local recurrence-free survival.

148 ) and 82% (95% CI, 79-84), and those for the local recurrence group were 71% (95% CI, 62-78) and 62%

149 sion, there was a 9% increase in the rate of local recurrence (hazard ratio, 1.09; 95% CI, 1.02-1.15;

150 Local recurrence HR for MRI-involved CRM was 3.50 (95% C

151 5%CI, 0.30-0.93), and less likely to develop local recurrence (HR = 0.54; 95%CI, 0.29-0.99).

152 thout adjuvant treatment was associated with local recurrence (HR, 1.97; 95% CI, 0.11-3.48; P = .02),

153 rascleral extension also was associated with local recurrence (HR, 3.2; 95% CI, 1.5-6.7; P = 0.003),

154 tumor diameter of 2 cm or greater predicted local recurrence (HR, 4.8 [95% CI, 1.8-12.7]), >1 risk f

155 14%) and systemic metastases with or without local recurrence in 226 patients (42%).

156 (18)F-PSMA-1007 PET/CT revealed local recurrence in 24.7% of patients (n = 62).

157 (18)F-rhPSMA-7 PET/CT revealed local recurrence in 43% of patients (113).

158 (68)Ga-PSMA ligand PET/CT indicated local recurrence in 68 of 107 patients (63.5%), distant

159 ters that correlate with true positivity for local recurrence in non-prostatectomy-treated patients.

160 serial (18)F-FDG PET/CT scans for detecting local recurrence in patients beyond 3 mo after nCRT and

161 specific considerations for the detection of local recurrence in the case of rectal cancer, as well a

162 The 5-year risk for local recurrence in the conserved breast was 3.3% (95% C

163 e primary outcome was absolute difference in local recurrence in the conserved breast, with a prespec

164 is original surgery, the patient developed a local recurrence in the foot, and over the subsequent 6

165 The reviewers assessed for local recurrence in the prostatectomy bed as well as LN

166 The primary endpoint was time to local recurrence in the resection cavity, assessed by bl

167 Although there was a higher rate of local recurrence in this cohort, pattern of first recurr

168 High rates of local recurrence in tobacco-related head and neck squamo

169 s (range, 92-257 days) after ablation showed local recurrences in two (7%) lesions that were original

170 l globe-retaining retreatment approaches for local recurrence, including proton beam therapy, brachyt

171 Endpoints were local-recurrence interval (LRI), distant disease-free in

172 The mechanism through which SEAL increases local recurrence is an important area for future researc

173 are associated with higher event rates, and local recurrence is associated with reduced overall surv

174 the primary site in patients at low risk for local recurrence is questionable.

175 (OS) and crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM) were c

176 study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in yo

177 the association between preoperative MRI and local recurrence (LR) as primary outcome, as well as dis

178 sociation with disease-specific death (DSD), local recurrence (LR), and distant recurrence (DR).

179 r non-small-cell lung cancer (NSCLC) is high local recurrence (LR).

180 S), disease-free survival (DFS), and time to local recurrence (LR).

181 The primary outcome measure was local recurrence (LR).

182 CIS) aims at reduction of the incidence of a local recurrence (LR).

183 reast tumors are predictive of breast cancer local recurrence (LR).

184 te the association of select covariates with local recurrence (LR).

185 ic death (DSD), distant recurrence (DR), and local recurrence (LR).

186 Women's Hospital tumor stage) and outcomes (local recurrence [LR], nodal metastases [NM], and death

187 Poor outcomes (local recurrence [LR], nodal metastasis [NM], and diseas

188 When considering rates of local recurrence, metastases, and late radiation adverse

189 d points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-spe

190 CT often causes significant morbidity due to local recurrences necessitating multiple surgeries.

191 Subhazard ratios for local recurrence, nodal metastasis, disease-specific dea

192 he development of poor skin cancer outcomes (local recurrence, nodal metastasis, distant metastasis,

193 ies that reported a disease-related outcome (local recurrence, nodal metastasis, distant metastasis,

194 True local recurrence occurred in 1 patient with concurrent i

195 Local recurrence occurred in 17 treated patients (6.8%).

196 Local recurrence occurred in 23% and margin status was t

197 Local recurrence occurred in 45 patients (4.6%) during t

198 ion and at least 2 years of CT surveillance, local recurrence occurred in 7% (five of 72), intrathora

199 Local recurrence occurred in 8 of 31 eyes (26%) treated

200 Only a single local recurrence occurred in cases with no risk factors

201 None of the two true local recurrences occurred at the site of the vessel.

202 Local recurrence occurs in one-quarter of children with

203 We report a case of local recurrence of basal cell carcinoma (BCC) and ocula

204 e associated with an increased likelihood of local recurrence of breast cancer.

205 END/DeltaEND) mice had significantly greater local recurrence of cancer following resection, elevated

206 An IBE was defined as local recurrence of DCIS or invasive carcinoma in the tr

207 by salvage rectal resection with no further local recurrence of disease (median follow-up 17 months)

208 (IJV) after subtotal thyroidectomy caused by local recurrence of papillary thyroid carcinoma is extre

209 alternative to enucleation in patients with local recurrence of PUM, yielding high rates of local co

210 Local recurrence of rectal cancer is more common after a

211 vehicle, gemcitabine significantly inhibited local recurrence of tumors, but not metastasis to distan

212 ll-mediated antitumor responses and inhibits local recurrence of tumors, consistent with observations

213 We evaluated 48 patients with local recurrence of uveal melanoma after primary treatme

214 In breast cancer (BC) patients, local recurrences often arise in proximity of the surgic

215 Nineteen patients (19%) had local recurrence only.

216 ves, more patients are at risk of developing local recurrence or a new primary tumour in previously i

217 not associated with increased percentage of local recurrence or decreased disease-free-survival.

218 There have been no cases of local recurrence or metastatic progression at median 21.

219 r glaucoma (NVG) and enucleation (mainly for local recurrence or NVG) were 27.0% and 19.5%, respectiv

220 some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in sele

221 (68)Ga-PSMA-11 did not differ (P > 0.05) in local recurrence or primary prostate cancer; however, th

222 A local recurrence or remnant tumor was found in two patie

223 carried out in 14 patients (9.5%) because of local recurrence or severe side effects.

224 e of endophthalmitis, orbital dissemination, local recurrence, or rhegmatogenous retinal detachment.

225 Estimated local recurrence, overall survival, and disease-specific

226 ns were associated with an increased rate of local recurrence ( P = 0.0003), which might indicate tha

227 tly associated with both PNI (P = 0.035) and local recurrence (P < 0.001).

228 le statistically significant risk factor for local recurrence (P = .00001).

229 tients and one of 31 LC patients experienced local recurrence (P = .21).

230 or the outcomes of use of TME (P < 0.01) and local recurrence (P = 0.01).

231 urvival (P = 0.317 and 0.655, respectively), local recurrence (P = 0.716 and 0.900, respectively), or

232 val, thereby observing tumor stage-dependent local recurrence, peritoneal carcinomatosis, and lung me

233 rectal coil is superior for the detection of local recurrence, PET/CT is superior for pelvic LN metas

234 ositive surgical margins, and development of local recurrence predicted for reduced DDFI (HR = 0.50,

235 In case of early detection of local recurrence, preservation of the globe can be warra

236 For local recurrence, pretreatment imaging features were not

237 This relatively low rate of local recurrence questions the need for adjuvant RT to t

238 results in a significantly increased 3-year local recurrence rate as compared with standard APE.

239 rate at 12 months; 5) Complication rate; 6) Local recurrence rate at 6 months.

240 The primary endpoint is the cumulative local recurrence rate at follow-up rectoscopy at 12 mont

241 nal verge), no significant difference in the local recurrence rate could be observed.

242 on is associated with a worse prognosis, but local recurrence rate does not differ significantly from

243 followed up for a minimum of 3 years, with a local recurrence rate of 2.4%, and a distant recurrence

244 l sample size of 198 is based on an expected local recurrence rate of 3% in the ESD group, 6% in the

245 The 4-year local recurrence rate was 0% (95% CI, 0% to 11%); the 4-

246 The local recurrence rate was 10%, the regional nodal recurr

247 a follow-up of 51 months (range, 1-151), the local recurrence rate was 4% and overall survival and di

248 The local recurrence rate was 6.0% overall and was highest f

249 Five-year estimated local recurrence rate was 6.6%.

250 The STS nomogram predicted the local recurrence rate with a C-index of 0.73.

251 h tumors close to fovea, without increase in local recurrence rate, and may therefore be preferable t

252 To investigate the local recurrence rates and margin to clearance end point

253 Local recurrence rates and margin to clearance end point

254 The local recurrence rates at 3 years [median follow-up, 3.4

255 h neoadjuvant chemoradiotherapy achieves low local recurrence rates in clinical stages II to III rect

256 The estimated local recurrence rates were 1.4% at 5 years, 1.8% at 7.5

257 tients), the overall 3- and 5-year actuarial local recurrence rates were 11% and 13%, respectively.

258 val based on the surgical approach; however, local recurrence rates were highest for percutaneously a

259 Local recurrence rates were similar: 12% versus 13% (P=0

260 abdominoperineal excision (ELAPE) regarding local recurrence rates within 3 years after surgery.

261 n addition to significantly increased 3-year local recurrence rates, the significantly increased inci

262 Despite higher local-recurrence rates for BCS, surgical type does not i

263 BRAF mutations, local recurrence, regional and distant metastasis, melan

264 as also associated with an increased risk of local recurrence (relative risk, 3.62).

265 ned with BS in diagnosing distant, bone, and local recurrence, shown by a greater area under the rece

266 advances in the management of rectal cancer, local recurrence still occurs.

267 erential resection margin, mesorectal grade, local recurrence, survival, and functional outcome.

268 Depending on the value placed on local recurrence, Tam remains a reasonable option for wo

269 therapeutic challenge with a higher risk of local recurrence than other types of melanoma correctly

270 radiotherapy) has been associated with more local recurrences than mastectomy, no differences in ove

271 For participants with postresection local recurrence, the median OS was 16 months from diagn

272 Risk factors for local recurrence, the need for prolonged follow-up, and

273 nts receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recu

274 e follow-up for patients with a high risk of local recurrence to assess for recurrence.

275 or overall survival, distant metastases, and local recurrence using only clinical factors, clinical f

276 ocal recurrence; the cumulative incidence of local recurrence was 1.44% (95% CI 0.51-2.38) with APBI

277 months (14-365 months), while median time to local recurrence was 43 months (9-185 months).

278 The median time to local recurrence was 43 months, the median time to dista

279 12-month freedom from local recurrence was 43% (95% CI 31-59) in the observati

280 The incidence of a local recurrence was comparable (13% vs. 15% at 10 years

281 Local recurrence was correlated with a higher risk for m

282 Local recurrence was detected up to 9.8 years after trea

283 Associations between R status and local recurrence was explored using X test.

284 When local recurrence was included in the model as a time-dep

285 Local recurrence was observed in 0% to 7% of the patient

286 A step-wise increase in local recurrence was observed in WT, neu-tolerant, and S

287 < .001 and P = .039, respectively), whereas local recurrence was significantly affected by ypN statu

288 of multiparametric MR imaging for diagnosing local recurrence were 88.5% (54/61), 84.6% (22/26), and

289 -Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99-99) at 1 year, 93%

290 older age, T2 disease, high tumor grade, and local recurrence were associated with reduced overall su

291 atients with small lymph node metastases and local recurrence were not excluded from treatment, consi

292 Higher rates of local recurrence were noted in HCC patients, which may r

293 Importantly, local recurrences were eliminated or greatly reduced in

294 low-up (range 6-48), 2 instances of cut-edge local recurrences were observed.

295 cally advanced pancreatic cancer and 10 with local recurrence) were included.

296 The primary endpoint, time to local recurrence, will be reported when participants hav

297 common cancers, but many patients experience local recurrence with metastatic disease.

298 maining 8589 patients, 861 (10.0%) developed local recurrence with no association to AL [adjusted haz

299 Most patients (n = 22) had local recurrence, with 82% (18 of 22) having unifocal di

300 atients (4.7%) with CBC melanoma experienced local recurrence, with a cumulative incidence of 11%.